Gastric Cancer

, Volume 22, Issue 5, pp 941–954 | Cite as

Epigenetic downregulation of MUC17 by H. pylori infection facilitates NF-κB-mediated expression of CEACAM1-3S in human gastric cancer

  • Shuye Lin
  • Yaping Zhang
  • Yingqi Hu
  • Bing Yang
  • Jiantao Cui
  • Jiaqiang Huang
  • Ji Ming Wang
  • Rui XingEmail author
  • Youyong LuEmail author
Original Article


Background and aims

Helicobacter pylori invades the mucosal barrier and infects the mucins of gastric epithelial cells. However, whether gastric carcinogenesis caused by H. pylori infection involves the membrane-bound mucins is unclear. This study explored the role of mucin 17 (MUC17) in gastric cancer (GC) associated with H. pylori infection.


The expression of MUC17 and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) was examined in human GC cells and tissues with H. pylori infection. Gain- and loss-of-function assays were performed to assess the role of MUC17 in regulating CEACAM1 in H. pylori-infected GC cells.


MUC17 was downregulated in H. pylori-infected GC cells and tissues in association with poor survival of GC patients. Downregulation of MUC17 was attributable to MUC17 promoter methylation mediated by DNA methyltransferase 1 (DNMT1) H. pylori-enhanced GC cell proliferation and colony formation associated with MUC17 downregulation. Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells. Moreover, MUC17 downregulated the expression of CEACAM1 variant 3S (CEACAM1-3S) in GC cells and tissues with H. pylori infection. Additionally, MUC17 downregulated CEACAM1 promoter activity via attenuation of NF-κB activation in GC cells.


MUC17 was epigenetically downregulated in GC with H. pylori infection. MUC17 inhibited H. pylori CagA translocation via attenuation of NF-κB-mediated expression of CEACAM1-3S in GC cells. Thus, MUC17 may serve as a valuable prognostic biomarker for H. pylori-associated GC.


H. pylori Mucin 17 CEACAM1 CagA Gastric cancer 



This work was supported by grants from National Natural Science Foundation of China (Grant nos. 81872021, 81572346, 81772502), Natural Science Foundation of Beijing Municipality (Grant no. 7182027), National Key Research and Development Program of China (2017YFC1308900), Beijing Municipal Commission of Health and Family Planning Project (PXM2018_026279_000005), National Bio-Tech 863 Program (no. 2012AA02A203), Beijing Nova Program (Z151100000315069), Beijing Talent Fund, and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201701). And we also thank the tissue bank of Peking University Cancer Hospital/Institute for providing gastric specimens.

Compliance with ethical standards

Conflict of interest

None of the authors have conflicts of interest that could potentially influence.

Ethics approval

This study was conducted with the approval of the Institutional Ethical Standards Committee.

Human rights statement and informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

Supplementary material

10120_2019_932_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 KB)
10120_2019_932_MOESM2_ESM.docx (35 kb)
Supplementary material 2 (DOCX 34 KB)
10120_2019_932_MOESM3_ESM.tif (4.2 mb)
Supplementary material 3 (TIF 4257 KB)
10120_2019_932_MOESM4_ESM.tif (149 kb)
Supplementary material 4 (TIF 148 KB)
10120_2019_932_MOESM5_ESM.tif (2 mb)
Supplementary material 5 (TIF 2027 KB)
10120_2019_932_MOESM6_ESM.tif (214 kb)
Supplementary material 6 (TIF 214 KB)
10120_2019_932_MOESM7_ESM.tif (7.8 mb)
Supplementary material 7 (TIF 7998 KB)
10120_2019_932_MOESM8_ESM.tif (12.9 mb)
Supplementary material 8 (TIF 13236 KB)
10120_2019_932_MOESM9_ESM.tif (779 kb)
Supplementary material 9 (TIF 779 KB)
10120_2019_932_MOESM10_ESM.tif (453 kb)
Supplementary material 10 (TIF 453 KB)
10120_2019_932_MOESM11_ESM.tif (5.7 mb)
Supplementary material 11 (TIF 5810 KB)


  1. 1.
    Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.CrossRefGoogle Scholar
  2. 2.
    Mahipal A, Choi M, Kim R. Second-line treatment of advanced gastric cancer: where do we stand? J Natl Compr Cancer Netw JNCCN. 2015;13(10):1281.CrossRefGoogle Scholar
  3. 3.
    Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer. 2013;13(1):1–8.CrossRefGoogle Scholar
  4. 4.
    Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–48.CrossRefGoogle Scholar
  5. 5.
    Lee KJ, Inoue M, Otani T, et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer. 2006;118(9):2315–21.CrossRefGoogle Scholar
  6. 6.
    Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863–73.CrossRefGoogle Scholar
  7. 7.
    Sigal M, Rothenberg ME, Logan CY, et al. Helicobacter pylori activate and expand Lgr5(+) stem cells through direct colonization of the gastric glands. Gastroenterology. 2015;148(7):1392–404.CrossRefGoogle Scholar
  8. 8.
    Li G, Wang Z, Wang Z, et al. Gastric cancer patients with Helicobacter pylori infection have a poor prognosis. J Surg Oncol. 2013;108(7):421–6.CrossRefGoogle Scholar
  9. 9.
    Qu M, Li L, Zheng WC. Reduced miR-490-3p expression is associated with poor prognosis of Helicobacter pylori induced gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21(15):3384–8.Google Scholar
  10. 10.
    Moniaux N, Junker WM, Singh AP, et al. Characterization of human mucin MUC17. J Biol Chem. 2006;281(12):23676–85.CrossRefGoogle Scholar
  11. 11.
    Dhanisha SS, Guruvayoorappan C, Drishya S, et al. Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit Rev Oncol Hematol. 2018;122:98–122.CrossRefGoogle Scholar
  12. 12.
    Senapati S, Sharma P, Bafna S, et al. The MUC gene family: their role in the diagnosis and prognosis of gastric cancer. Histol Histopathol. 2008;23(12):1541–52.Google Scholar
  13. 13.
    Resta-Lenert S, Das S, Batra SK, et al. Muc17 protects intestinal epithelial cells from enteroinvasive E. coli infection by promoting epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol. 2011;300(6):G1144.CrossRefGoogle Scholar
  14. 14.
    Pan Y, Lin S, Xing R, et al. Epigenetic upregulation of metallothionein 2A by diallyl trisulfide enhances chemosensitivity of human gastric cancer cells to docetaxel through attenuating NF-κB activation. Antioxid Redox Signal. 2016;24(15):839–54.CrossRefGoogle Scholar
  15. 15.
    Lin S, Lin B, Wang X, et al. Silencing of ATP4B of ATPase H+/K+ transporting beta subunit by intragenic epigenetic alteration in human gastric cancer cells. Oncol Res. 2017;25(3):317–29.CrossRefGoogle Scholar
  16. 16.
    Sho K, Norishige Y, Seiya Y, et al. DNA methylation and histone H3-K9 modifications contribute to MUC17 expression. Glycobiology. 2011;21(2):247–56.CrossRefGoogle Scholar
  17. 17.
    Zhang BG, Hu L, Zang MD, et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development. Oncotarget. 2016;7(9):9788–800.Google Scholar
  18. 18.
    Yan J, Zhang M, Zhang J, et al. Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancer. Biochem Biophys Res Commun. 2011;408(1):99–102.CrossRefGoogle Scholar
  19. 19.
    Javaheri A, Kruse T, Moonens K, et al. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2016;2:16243.CrossRefGoogle Scholar
  20. 20.
    Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45–60.CrossRefGoogle Scholar
  21. 21.
    Wang F, Meng W, Wang B, et al. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196–202.CrossRefGoogle Scholar
  22. 22.
    Hagymási K, Tulassay Z. Helicobacter pylori infection: new pathogenetic and clinical aspects. World J Gastroenterol. 2014;20(21):6386–99.CrossRefGoogle Scholar
  23. 23.
    Noto JM, Peek RM. Helicobacter pylori: an overview. Methods Mol Biol. 2012;921(2):7–10.CrossRefGoogle Scholar
  24. 24.
    Shi D, Qiu XM, Bao YF. Effects of Helicobacter pylori infection on MUC5AC protein expression in gastric cancer. Future Oncology. 2013;9(1):115–20.CrossRefGoogle Scholar
  25. 25.
    Park JS, Yeom JS, Seo JH, et al. Immunohistochemical expressions of MUC2, MUC5AC, and MUC6 in normal, Helicobacter pylori infected and metaplastic gastric mucosa of children and adolescents. Helicobacter. 2015;20(4):260–8.CrossRefGoogle Scholar
  26. 26.
    Shi D, Qiu XM, Yan XJ. The changes in MUC5AC expression in gastric cancer before and after Helicobacter pylori eradication. Clin Res Hepatol Gastroenterol. 2014;38(2):235–40.CrossRefGoogle Scholar
  27. 27.
    Jr Crawley GJ, Hicks SC. JW, et al. MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun. 2002;291(3):466–75.CrossRefGoogle Scholar
  28. 28.
    Backert S, Blaser MJ. The role of CagA in the gastric biology of Helicobacter pylori. Can Res. 2016;76(14):4028.CrossRefGoogle Scholar
  29. 29.
    Yoon JH, Seo HS, Choi SS, et al. Gastrokine 1 inhibits the carcinogenic potentials of Helicobacter pylori CagA. Carcinogenesis. 2014;35(11):2619–29.CrossRefGoogle Scholar
  30. 30.
    Aspholmhurtig M, Dailide G, Lahmann M, et al. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science. 2004;305(5683):519–22.CrossRefGoogle Scholar
  31. 31.
    Evans DJ Jr, Evans DG.Helicobacter pylori adhesins: review and perspectives. Helicobacter. 2000;5(4):183–95.CrossRefGoogle Scholar
  32. 32.
    Lindén SK, Sheng YH, Every AL, et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog. 2009;5(10):e1000617.CrossRefGoogle Scholar
  33. 33.
    Bugaytsova JA, Björnham O, Chernov YA, et al. Helicobacter pylori adapts to chronic infection and gastric disease via pH-responsive BabA-mediated adherence. Cell Host Microbe. 2017;21(3):376–89.CrossRefGoogle Scholar
  34. 34.
    Yu J, Leung WK, Go MY, et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut. 2002;51(4):480–4.CrossRefGoogle Scholar
  35. 35.
    Yanai A, Maeda S, Hikiba Y, et al. Clinical relevance of Helicobacter pylori sabA genotype in Japanese clinical isolates. J Gastroenterol Hepatol. 2007;22(12):2228–32.CrossRefGoogle Scholar
  36. 36.
    Feige MH, Sokolova O, Pickenhahn A, et al. HopQ impacts the integrin α5β1-independent NF-κB activation by Helicobacter pylori in CEACAM expressing cells. Int J Med Microbiol IJMM. 2018;308(5):527–33.CrossRefGoogle Scholar
  37. 37.
    Grayowen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433–46.CrossRefGoogle Scholar
  38. 38.
    Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-α converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem. 2003;278(5):3386.CrossRefGoogle Scholar
  39. 39.
    Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014;20(18):5461–73.CrossRefGoogle Scholar
  40. 40.
    Correa P. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol. 2009;44(4):239–48.CrossRefGoogle Scholar
  41. 41.
    Díaz P, Valenzuela MV, Bravo J, et al. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol. 2018;9:5.CrossRefGoogle Scholar
  42. 42.
    Maeda M, Moro H, Ushijima T. Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway. Gastric Cancer. 2016;20(Suppl 1):1–8.Google Scholar
  43. 43.
    Yonezawa S, Higashi M, Yamada N, et al. Significance of mucin expression in pancreatobiliary neoplasms. J Hepato Biliary Pancreat Sci. 2010;17(2):108.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)Peking University Cancer Hospital & InstituteBeijingPeople’s Republic of China
  2. 2.College of Life Sciences and Bioengineering, School of ScienceBeijing Jiaotong UniversityBeijingPeople’s Republic of China
  3. 3.Cancer and Inflammation Program, Center for Cancer ResearchNational Cancer InstituteFrederickUSA

Personalised recommendations